HSP90B1 and adrenal cortex carcinoma: We demonstrated that several members of the HSP90 (HSP90B1, HSP90B2P) and PI3K family (AKT2) were linked to shorter OS, DFS, and adverse clinical features in ACC including advanced stage and metastasis, supporting the use of the HSP90 and PI3K inhibitors in combination.